KOL Overview:
Dr. Patrick Forde is an adjunct professor of Oncology at Johns Hopkins Medicine. He is also the Co-director of the Division of Upper Aerodigestive Malignancies and the Director of the Thoracic Oncology Clinical Research Program. As an accomplished researcher, his presentations from the stage are often celebrated by his peers, and he is a very active contributor to the lung cancer social media community, His tweets are among the most engaging among his peers to include discussions on major clinical trials such as LAURA, CHECKMATE 816, CHECKMATE 73L, KEYNOTE-671, and PACIFIC-2. As the lead author of CHECKMATE 816, Dr. Forde 's presentations were highlighted by his peers and he also took the opportunity to support his fellow investigators.
Outstanding work from Drs. Julie Stein-Deutsch & Janis Taube, we are so fortunate to work with them & our many pathology colleagues on CheckMate 816! Pathologic response (even down to the 1% level) is correlated with longer term outcome after neoadjuvant immunotherapy. #lcsm https://t.co/JCAybhecAJ pic.twitter.com/jkjAKiVSI2
— Patrick Forde (@FordePatrick) November 4, 2023
Very promising results from Checkmate-816 presented by @FordePatrick #AACR21: 3 cycles of neoadjuvant chemo/Nivolumab vs. 3 cycles of chemo. Look at that OR (13.94!) pic.twitter.com/Jz2nYCLrGk
— Toni Choueiri, MD (@DrChoueiri) April 10, 2021
Advocating Evidence-Based Approaches
Dr. Forde shares both good and bad news regarding clinical trial outcomes. Below is an example of the update on CHECKMATE 73L, and his commentary on the impact on patient care:
Concurrent immunotherapy (+ chemo) with standard radiation is not a viable approach in nsclc, now a second negative phase 3 trial after pacific 2 #lcsm https://t.co/CEFoi923zW
— Patrick Forde (@FordePatrick) May 11, 2024
Dr. Forde was one of the first key opinion leaders to celebrate the success of the LAURA trial and declare a new standard of care:
Impressive increase in PFS with consolidation osimertinib after CRT for pts w unresectable stage III lung cancer. Crossover on progression 82% higher than in most other studies. OS far from mature. Will be adopted as a new standard where it is available I believe. #lcsm #ASCO24 pic.twitter.com/vO4uuOVtAo
— Patrick Forde (@FordePatrick) June 2, 2024
Engaging in Constructive Discussions
Dr. Forde’s social media presence is marked by his active participation in constructive discussions. Whether it’s analyzing the implications of the LAURA trial or debating the merits of crossover in clinical trials, he engages his peers with thought-provoking questions and evidence-based arguments
On crossover - in 2 phase 3 nsclc trials (LAURA & KN189) where in-study drug was provided to pts w progression on control arm, rates were 81% & 57%. So my question to colleagues @Timothee_MD @oncology_bg @Alfdoc2 What is an acceptable rate of crossover? 57% 81% or 100%? #lcsm pic.twitter.com/H1doeOj3Wg
— Patrick Forde (@FordePatrick) June 24, 2024
His interactions indicate a persona committed to intellectual rigor and collaborative advancement.
It would be useful to trainees to have consensus on a benchmark, e.g. (& not to dig out the tweets) when cm816 was published a principal criticism was that crossover was not ~100%. Before #ASCO24 it was the main LAURA prebuttal until it was clear study drug was provided at PD.
— Patrick Forde (@FordePatrick) June 24, 2024
Social Media Style
Dr. Patrick Forde is a modern key opinion leader, respected for his research and presentations from the stage, and also a key member of the social discussions on clinical trials that impact patient care across modalities of lung cancer treatment. He engages with the tweets of his peers and shares data to spur discussions and debate. His tweets and research carry significant weight with his colleagues and he recognizes the arguments of physicians across the spectrum of a debate.
Nice to meet @FordePatrick in person . His trial ,checkmate 816 , is really Landmark. What ever new data comes up ,3 cycles of Neo Adjuvant Nivolumab will be THE most cost effective approach and will be bench mark for any new longer duration IO data in early stage NSCLC .👍👍… pic.twitter.com/UaIFaxwezq
— Dr Amol Akhade (@SuyogCancer) October 22, 2023
Sentiment
Clinical Trial / Sentiment | Content |
---|---|
CHECKMATE 73L NEGATIVE
|
|
FLAURA2 NEUTRAL
|
|
LAURA POSITIVE
|
|
PACIFIC-2 NEUTRAL
|
Total Payments 2017-2023 to Dr.PATRICK FORDE: $191,520
Company | Total | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
E.R. Squibb & Sons, L.L.C. |
$43,109 |
$8,105 |
$137 |
$0 |
$0 |
$5,850 |
$22,129 |
$6,889 |
Regeneron Pharmaceuticals, Inc. |
$24,997 |
$0 |
$0 |
$0 |
$0 |
$0 |
$3,101 |
$21,896 |
AstraZeneca UK Limited |
$23,580 |
$0 |
$7,947 |
$0 |
$1,250 |
$4,110 |
$4,795 |
$5,478 |
AstraZeneca Pharmaceuticals LP |
$22,038 |
$506 |
$389 |
$1,385 |
$0 |
$3,425 |
$11,777 |
$4,557 |
GENZYME CORPORATION |
$16,949 |
$0 |
$0 |
$0 |
$0 |
$2,616 |
$14,333 |
$0 |
Top Tweets
KOL PulseRank
Clinical Trial | Tweets | Peer Outreach | Peer Engagement |
CHECKMATE 816 | 1 | 12 | 18 |
CHECKMATE 73L | 1 | 7 | 16 |
KEYNOTE-671 | 3 | 9 | 15 |
PACIFIC-2 | 2 | 15 | 14 |